Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development.

14 Feb 2010

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Biologics, Inc., the leading cancer management company in the United States, announces that its Oncology Clinical Trial Services division has been selected by the National Marrow Donor Program® (NMDP), a nonprofit organization that facilitates unrelated hematopoietic cell transplants.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

British rhubarb could be a potential source of anti-cancer agent

Eating rhubarb baked in a crumble is not only tasty it may also be the best way to take advantage of its health benefits, and could lead to the development of new cancer treatments.

From Sheffield Hallam University 11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Micromet outlines the design of registration study for blinatumomab in ALL

At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.

11 Feb 2010

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

Elbit Imaging Ltd. announces that its associated company (approximately 28% holding on a fully diluted basis), Gamida Cell Ltd. ("Gamida Cell") through the Gamida-Teva Joint Venture (JV), announced today that the Data Monitoring Committee ("DMC") has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

11 Feb 2010

DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx

The Gamida Cell-Teva Joint Venture (JV) announced today that the Data Monitoring Committee (DMC) has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

10 Feb 2010

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.

10 Feb 2010

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell Lymphoma Consortium (MCLC) Scientific Workshop will be published in the March 2010 issue of Leukemia & Lymphoma. Traditionally accessible to subscribers for period of one year, Leukemia and Lymphoma has agreed to make this report available to the public for one month -- Mantle Cell Lymphoma: Report of the 2009 MCL Consortium Workshop.

10 Feb 2010

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.

9 Feb 2010

Researchers explore cellular networks that regulate cell morphology

Cellular imaging offers a wealth of data about how cells respond to stimuli, but harnessing this technique to study biological systems is a daunting challenge.

9 Feb 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

Scientists identify enzyme mutations in AML patients

A study published online on February 8 in the Journal of Experimental Medicine (www.jem.org) reports that several distinct mutations found in a subset of patients with acute myelogenous leukemia (AML) result in excess production of the same metabolite.

9 Feb 2010

Cord Blood America finalizes agreement to process and store cord blood specimens for BioCells

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has finalized an agreement to process and store cord blood specimens for BioCells, Inc., headquartered in Argentina, and its affiliates in Peru, Colombia, Bolivia, Panama and Puerto Rico.

8 Feb 2010

EpiCept announces at-the-market program for selling common stock shares

EpiCept Corporation announced today that it has established an at-the-market program through which it may sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to $15 million. Maxim Group LLC is acting as sales agent on the program.

6 Feb 2010

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

CORD:USE Cord Blood Bank and its program at South Miami Hospital are being featured on CNN en Espanol's show "Salud." This story on the importance of cord blood donation aired this week and can be seen Friday, February 5 at 9:30 a.m. EST and Sunday, February 7 at 9 a.m. EST and 3 p.m. EST on CNN en Espanol.

5 Feb 2010

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

Oxford Finance Corporation today announced that it is the agent and primary lender for a $25 million credit facility provided to EUSA Pharma. MidCap Financial and Silicon Valley Bank are co-lenders in the transaction.

5 Feb 2010

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics.

5 Feb 2010

Scientists discover new technique to destroy individual diseased cells

Using lasers and nanoparticles, scientists at Rice University have discovered a new technique for singling out individual diseased cells and destroying them with tiny explosions.

5 Feb 2010

Leukemia News and Research

Further Reading

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Second-quarter fiscal 2010 results announced by Pharmacyclics

British rhubarb could be a potential source of anti-cancer agent

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Micromet outlines the design of registration study for blinatumomab in ALL

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Biogen Idec reports 2009 fourth quarter and full year earnings

Researchers explore cellular networks that regulate cell morphology

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Scientists identify enzyme mutations in AML patients

Cord Blood America finalizes agreement to process and store cord blood specimens for BioCells

EpiCept announces at-the-market program for selling common stock shares

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Scientists discover new technique to destroy individual diseased cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News